PPAR-ϒ pathway to vascular dysfunction.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23040065.
- Also identified by DOI 10.1016/j.cmet.2012.09.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Humans with dominant-negative (DN) mutations in PPAR-ϒ develop early onset hypertension. A recent study by Pelham et al. (2012) shows that loss of PPAR-ϒ repression of the Rho kinase pathway leads to altered vascular function via a smooth-muscle-dependent pathway that is independent of NO and oxidant stress.